Amalgamated Bank Boosts Stake in Vaxcyte, Inc. (NASDAQ:PCVX)

Amalgamated Bank grew its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 8.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,081 shares of the company’s stock after acquiring an additional 322 shares during the quarter. Amalgamated Bank’s holdings in Vaxcyte were worth $466,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. boosted its position in Vaxcyte by 68.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 21,466 shares of the company’s stock valued at $2,453,000 after purchasing an additional 8,685 shares in the last quarter. Harbor Capital Advisors Inc. boosted its holdings in shares of Vaxcyte by 392.4% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 40,342 shares of the company’s stock valued at $3,046,000 after buying an additional 32,149 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of Vaxcyte by 18.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,176,181 shares of the company’s stock worth $216,966,000 after buying an additional 498,359 shares during the last quarter. Russell Investments Group Ltd. bought a new position in shares of Vaxcyte during the 1st quarter worth approximately $1,288,000. Finally, Tri Locum Partners LP purchased a new stake in Vaxcyte during the second quarter valued at approximately $8,559,000. 96.78% of the stock is owned by institutional investors.

Vaxcyte Stock Performance

Shares of PCVX stock opened at $86.83 on Friday. Vaxcyte, Inc. has a fifty-two week low of $48.24 and a fifty-two week high of $121.06. The firm has a market capitalization of $10.82 billion, a PE ratio of -18.88 and a beta of 1.01. The stock’s 50-day simple moving average is $110.67 and its 200-day simple moving average is $88.65.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($1.10) by $0.27. During the same quarter last year, the company posted ($0.91) earnings per share. Sell-side analysts forecast that Vaxcyte, Inc. will post -4.14 earnings per share for the current year.

Insider Transactions at Vaxcyte

In other Vaxcyte news, CEO Grant Pickering sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $78.98, for a total value of $1,184,700.00. Following the completion of the transaction, the chief executive officer now directly owns 478,888 shares of the company’s stock, valued at approximately $37,822,574.24. The trade was a 3.04 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Andrew Guggenhime sold 42,000 shares of the company’s stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $115.39, for a total value of $4,846,380.00. Following the completion of the sale, the chief financial officer now owns 90,383 shares in the company, valued at approximately $10,429,294.37. This represents a 31.73 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 117,464 shares of company stock worth $12,640,276 over the last 90 days. 3.10% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on PCVX. Leerink Partners lifted their price target on shares of Vaxcyte from $106.00 to $153.00 and gave the stock an “outperform” rating in a report on Tuesday, September 3rd. Bank of America upped their target price on Vaxcyte from $101.00 to $140.00 and gave the company a “buy” rating in a research report on Wednesday, September 4th. Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a report on Wednesday, November 6th. Needham & Company LLC restated a “buy” rating and set a $140.00 price objective on shares of Vaxcyte in a report on Wednesday, November 6th. Finally, Mizuho increased their price objective on shares of Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a research report on Tuesday, September 10th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $147.50.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.